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ABSTRACT
Aims: To create a standardized home exercise therapy program that
could be implemented by international sites to provide a consistent
level of therapeutic intervention for pediatric patients participating
in an ongoing Phase-III, randomized, controlled trial of repeat
abobotulinumtoxinA injections for pediatric upper limb spasticity
(NCT02106351). Methods: Physical therapists, occupational therapists,
and medical doctors worked collaboratively to design an exercise
therapy program to be implemented in the home setting. In this art-
icle, we describe the development process and the finalized program
that is currently being used in the Phase-III trial. Results: The final
program is presented as a “toolbox” for therapists, and includes a
standardized step-wise process for choosing the most appropriate
exercises and functional activities to achieve the agreed treatment
goals of each abobotulinumtoxinA injection. The core toolbox
includes: a clear protocol for clinicians, information sheets, signature
of commitment forms, exercise score charts, and the library of exer-
cises and functional activities that therapists choose from to aid the
patient in achieving their treatment goals. Conclusions:
Implementation of this home therapy program provides a standar-
dized background of good practice against which to test the efficacy
of abobotulinumtoxinA. Preliminary data show that the program is
readily accepted by patients and their families.
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Although cerebral palsy (CP) is considered “non-progressive” in terms of the original
brain lesion, the underlying upper motor neuron syndrome causes progressive musculo-
skeletal pathology (Kerr Graham & Selber, 2003), ultimately resulting in reduced func-
tional use of the limbs, deformity, and, in some children, a learned non-use of the affected
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limb (Hoare & Imms, 2004). Therefore, a key aim of therapy is to improve motor function,
support motor development, and enable participation in age-appropriate activities (Strobl
et al., 2015). With this aim in mind, it is generally well-accepted that occupational and/or
physical therapy should form the foundation of long-term treatment plans for CP, because
such treatment focuses on the development of skills necessary for the performance of
activities for daily living and independence (Steultjens et al., 2004).
It has been estimated that between 50% and 70% of children with CP will have upper
limb spasticity, with higher prevalence rates in children with hemiparesis (Colver, Fairhurst,
& Pharoah, 2014; Santos et al., 2015). Botulinum toxin type-A (BoNT-A) is a commonly
used pharmacologic option to reduce upper limb spasticity (Hoare, 2014; Strobl et al.,
2015), and accumulating evidence now suggests that long-term BoNT-A treatment is more
effective when combined with a physical/occupational therapy intervention, compared to
BoNT-A therapy alone (Ferrari et al., 2014; Hoare et al., 2010; Karaca, Unlu, Kose, Gonen,
& Cakci, 2016; Lin et al., 2015; Wallen, O’Flaherty, & Waugh, 2007). Based on data from
10 randomized controlled trials, the most recent Cochrane review concluded that “BoNT-A
should not be used in isolation but should be accompanied by planned occupational ther-
apy (Hoare et al., 2010).” However, while the utility of BoNT-A in managing upper limb
spasticity due to CP is well established through clinical use, the current literature remains
largely limited to small clinical trials of short duration, often without an adequate compara-
tor (Delgado et al., 2010; Reeuwijk, van Schie, Becher, & Kwakkel, 2006). Few trials have
provided adequate information on the rehabilitation strategies (if any) employed.
To address such evidence gaps, an international multicenter Phase-III clinical trial of
abobotulinumtoxinA (DysportVR ; Ipsen, Wrexham, UK) for upper limb spasticity due to
CP (NCT02106351) was initiated in 2014 with the objective of demonstrating the effi-
cacy and safety of abobotulinumtoxinA across repeat injections. Like its associated trial
in pediatric patients with lower-limb spasticity (Delgado et al., 2016), this study of pedi-
atric upper limb spasticity (PULS) has been designed to include modern standards of
evaluation such as the assessment of efficacy across the different International
Classification of Functioning, Disability and Health (ICF) domains of body function
and structure, activity and participation. Considering the necessity of combining BoNT-
A with occupational and/or physical therapy, and since not every child has access to the
same standards of care, it was decided to include a standardized home therapy program
to be followed in conjunction with abobotulinumtoxinA injections into the upper arm
(for all patients, in both the control and active treatment arms).
Our objective was to create a home therapy program that can be implemented inter-
nationally for all patients participating in the trial. We describe here the development of
the program and the processes required for its standardized implementation in the
Phase-III PULS trial. Although the trial is ongoing, a subset of children completed their
treatment cycles and a preliminary feasibility report is also presented.
Methods
An international working group formed by nine occupational therapists, physical therapists,
and medical doctors was invited by the principle investigator of the PULS Phase-III trial to
design the Home Exercises Therapy Program (HETP) over a series of face-to-face meetings
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and telephone calls. Members of the working group were all specialists in their respective
fields and drawn from the international study sites involved in the Phase III study. Study
sites were recruited based on their extensive experience in the use of BoNT-A treatment for
pediatric CP spasticity management and ability to participate in clinical trials. The develop-
ment process began in May 2013 and was completed in March 2014. Final HETP documen-
tation was reviewed and approved by the working group before submitting the program for
peer-review by the steering committee of the Phase III trial, consisting of specialist pediatric
neurologists and neurorehabilitation doctors, and then for Institutional Review Board (IRB)
approval as part of the overall appraisal of the Phase-III PULS trial protocol. No significant
changes were required to the proposed materials at either stage.
Throughout the development process, the working group considered the needs of the
target patient population for the PULS trial (NCT02106351), which recruited male and
female children (2–17 years old) with a diagnosis of CP (GMFCS level I-IV and MACS
I-V). Patients were required to have increased muscle tone/spasticity in at least one
upper limb, with a Modified Ashworth Scale (MAS) (Bohannon & Smith, 1987) score
2 in the primary targeted muscle group (PTMG) of the study limb. The PTMG could
be the elbow or wrist flexors, and additional muscles of the upper limb could be
injected based on the child’s goals and clinical presentation.
Literature Search
First, to investigate whether similar programs had been developed previously, and to
inform the development of the HETP, a literature search was performed in June 2013
using a combination of Medical Subject Headings terms and key words. Key words of
relevance to protocol development were: cerebral palsy and home program. Language
(English only) and date limits (January 2000–June 2013) were also applied. The search
was performed using the PubMed and Medline databases. Bibliographic reference lists
of papers identified during the database search were reviewed manually by two
reviewers to identify any relevant studies not identified through the electronic database
searches. There were no disagreements between the reviewers.
Overall, nine articles were identified and all were reviewed in detail (Campbell et al., 2012;
Daichman, Johnston, Evans, & Tecklin, 2003; Harbourne, Willett, Kyvelidou, Deffeyes, &
Stergiou, 2010; Kim et al., 2012; Novak, 2011; Novak & Cusick, 2006; Novak, Cusick, &
Lannin, 2009; Novak, Cusick, & Lowe, 2007; Piggot, Hocking, & Paterson, 2003; Seifart,
Unger, & Burger, 2010). Taken collectively, the literature strongly supported the use of
home programs for children with CP. Of the nine articles, the working group agreed that
the series of three studies by Novak et al. provided the most robust and repeatable source of
evidence, clearly outlining the process for creating home programs (Novak & Cusick, 2006;
Novak et al., 2009; Novak et al., 2007). The information from these identified articles was
then used to inform the working group during their development of the final program.
Development of the Home Therapy Program
Novak et al. defined five key phases for development of a home therapy program: (1)
establishing a collaborative relationship with the child’s parent/caregiver; (2) collaborative
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goal setting; (3) constructing the home therapy program; (4) supporting the program
implementation; and (5) evaluating the outcomes (Novak & Cusick, 2006). To implement
the five key phases of HETP development the working group determined that practical
guidelines for selecting and teaching the home program exercises/activities needed to be
defined. Using the approach outlined by Novak et al., the working group met in person to
define what components (i.e. documents and training) the HETP should include and the
process for development (i.e. task list to develop each component, Table 1).
The working group decided that core components of the HETP would include a
library of therapeutic exercises/activities, advice on goal setting and goal attainment
scaling (GAS, which is used as an efficacy outcome measure in the Phase-III study),
and supporting information materials for the patients and their families. Thus, three
separate subgroups:
1. Developed the library of exercises and functional activities that could be expected
to be beneficial following an injection of abobotulinumtoxinA. Exercises were
proposed and chosen based on the working group’s own experience. The sub-
group also arranged the photographs of the exercises being demonstrated for use
to ensure the manual was self-explanatory.
2. Reviewed the literature for GAS in spasticity management (Steenbeek, Ketelaar,
Galama, & Gorter, 2007; Turner-Stokes, 2009) and examples of suitable treatment
goals and developed a manual to train clinicians on developing GAS goals and
incorporating the goals in the patient’s HETP. Emphasis was placed on building a
collaborative relationship based on family preferences and setting SMART (specific,
measurable, achievable, relevant, and timed) goals (Bovend’Eerdt, Botell, & Wade,
2009). All therapists received detailed training on the implementation of GAS,
including goal setting, negotiation, and scoring.
3. Developed supporting materials and documentation required for standardized
implementation of the HETP, including introduction of the program to the par-
ticipating families, parent/child information sheets, commitment forms, and an
incentive chart.
All HETP documents were translated (and back-translated as a quality control check)
from English into Arabic, Czech, Hebrew, French, Polish, Spanish, and Turkish.
Table 1. Task List
Key phase Task list
Establishing a collaborative relationship Develop the parent/child information sheets and commitment forms
Collaborative goal setting Review and finalize the GAS manual
Develop SMART goal and GAS training materials
Constructing the home program Develop an introduction for the home therapy manual including the
stepwise process that should be used to implement the program
Develop flow sheet on how to select appropriate exercises
Create a library of activities including description of exercises by joint
with pictures
Finalize global activities chart
Supporting program implementation Review and finalize incentive chart
Develop training materials for therapists
Evaluating outcomes No further work related to the home program development as the
outcomes were established as part of the overall study protocol
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Implementation and Evaluation
Therapists at all sites received detailed face-to-face training on the implementation of the
HETP, including how to introduce and explain the program to the patients and their families,
use the manual to choose relevant exercises/activities, as well as goal setting, negotiation, and
GAS scoring. Success of the HETP was evaluated by family acceptance to commit to the pro-
gram and to use it throughout the Phase-III PULS trial. At each trial visit (Week 2, Week 4,
Week 6, Week 12, and Week 16), the patient/parent/caregiver was asked to report on the fre-
quency of home exercises by filling in a score chart or a paper diary.
Results
The finalized HETP was presented as a “toolbox” for clinicians at each trial site (in their
respective language), and included patient and family materials, a library of exercises
and functional activities, and a detailed protocol for clinicians. The toolbox is provided
in the supplemental appendix to this article.
Patient and Family Materials
A set of six documents was developed for use by patients and their families.
1. Separate patient (if applicable) and parental guardian information sheets were
written in the first person to engage the patient and their families, and were
designed as templates that could be easily personalized. Both types of informa-
tion sheet were structured to explain how the patient’s muscles are different due
to spasticity, the purpose of the HETP, and provide tips on how to make the
exercises more fun. The parental guardian information sheet also included infor-
mation on the general principles of the program and any precautions.
2. Separate patient (if able) and parental guardian signature of commitment forms
explaining the patient’s diagnosis, the reason for receiving BoNT-A injections,
and the reason the patient should participate in the HETP.
3. Exercise score charts to record the exercises performed each day. Exercises were
scored as “good”, “incomplete”, or “not done.”
4. Library of exercises and functional activities (hard copy folder).
Library of Exercises and Functional Activities
The final library of therapeutic exercises/activities was presented on a CD-ROM and in
a hard copy binder. Exercises were organized by primary target joint. Passive range of
motion (PROM) exercises was developed for the shoulder adductor and internal rotator
muscles, elbow flexor muscles, forearm pronator muscles, and wrist/finger flexor
muscles. Patients and families were instructed that the PROM exercises needed to be
sustained stretches lasting 20–60 seconds per repetition, with at least five repetitions per
day. Strengthening exercises were developed for the shoulder abductor and external
rotator muscles, elbow extensor muscles, forearm supinator muscles, and wrist/finger
extensor muscles. The minimum expectation was that the patient would engage in
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therapeutic strengthening exercises and functional activities at least five times per week
for at least 15minutes per session (based on the recommendation of at least one hour
per week as decribed by Novak et al., 2009).
If active GAS goals were identified, the patients were also required to practice the
goals. Based on the child’s individual presentation, the therapist decided whether these
active exercises/functional activities should be performed independently or with assist-
ance, and whether they should be performed against gravity or resistance.
Protocol for Clinicians
Clinicians were provided a detailed protocol for goal setting and implementation of the
HETP, including:
1. Information on how to set goals using GAS methodology
2. A detailed description of the stepwise process for choosing the most appropriate
exercises/activities to achieve the agreed goals of treatment
3. A description of how to discuss the HETP with the patient and their paren-
tal guardians.
The process for goal setting and goal assessment was based on published GAS meth-
odology, and we used available GAS materials for our training (Turner-Stokes, 2009). In
Figure 1. Standardized processes for (a) exercise selection based on goals (b) engaging patients
and families.
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the first step, the research team along with the patient and family agreed to between
one and three goals. GAS goals were individualized to the patient, and for the purposes
of the Phase-III study, the goals were categorized into four sub-domains: active func-
tion, passive function, pain, and other. Examples of goals could include increased inde-
pendence with self-care or improvements in leisure activities (active function),
improved passive range for the ease of hygiene and prevention of skin breakdown (pas-
sive function), reduction of pain in the upper limb (pain), or another goal that is mean-
ingful to the patient but does not meet the criteria of the first three sub-domains
(other). Next, the research team established the muscles to be injected based on the
patient’s goals and clinical presentation. A standardized flow chart was also developed
to provide guidance on which exercises/activities to choose (Figure 1(a)) based on the
patient’s independence level to perform the task or movement targeted. As part of the
protocol, all therapists were required to provide the patient and their families with:
1. At least one exercise for improving PROM, usually restricted by the increased
tone of the muscles injected. If the patient did not have full PROM following
abobotulinumtoxinA injection, the protocol expected that PROM exercises were
completed for a minimum of 5 days per week to stretch the injected muscles.
2. A list of age appropriate exercises or functional activities to promote active range
of motion/strengthening for the muscle groups opposing those that were injected.
3. Advice to practice the agreed functional tasks.
The HETP was introduced to the family using six steps designed to ensure under-
standing and commitment from all involved (Figure 1(b)). The final protocol accepted
that flexibility in the chosen goals and exercises is required, and allowed therapists to
tailor exercises based on family feedback. As an example, one patient wished to
“perform better” when playing volleyball and the goal achievement levels were defined
such that the expected outcome (score 0) at 6-weeks post-injection was to “hit a beach
ball (i.e. larger ball) overhead with two hands at least 80% of the time,” the better than
expected outcome (score þ1) was to “hit a volleyball overhead with two hands at least
80% of the time,” and the much better than expected outcome (score þ2) was to “hit a
volleyball overhead with two hands and symmetrical movement of left and right side.”
The exercises chosen to support this goal included PROM elbow extension as well as
tricep dips and wall push-ups for strengthening. The functional activity was to practice
hitting a beach ball overhead working on the use of the left upper arm.
Study personnel at each of the 31 sites were trained on implementation of the HETP at
a series of training the trainer meetings. At least one clinician from each country in the
trial received advanced training so that they could provide suitable training and support
to clinicians from other sites in that country. Refresher courses were provided every 9 to
12months to ensure a high quality of training was maintained across all trial sites.
Evaluation of the Program
The Phase-III PULS trial is ongoing at 31 sites across eight countries. As of January
2017, 65 children from 20 international sites had completed their injection cycles,
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providing interim information on the success of the HETP. Thus far, all families agreed
to follow the HETP (as evidenced by 100% agreement in the parent/caregiver commit-
ment forms). Overall, 61 children (94%) began the HETP immediately following injec-
tion of abobotulinumtoxinA and two families began with a delay of a week and two
others after a delay of 1–4months (unknown reasons). Two-thirds of families opted to
complete the prescribed exercises five times per week, and one-third of families opted
to complete the prescribed exercises once daily (i.e. 7 times per week).
Of the 65 children who had completed the Phase-III PULS trial by December 2016;
seven received one abobotulinumtoxinA treatment (i.e. completed one treatment cycle),
21 received two treatments, 25 received three treatments, and 12 received four treat-
ments. All but two of the 65 families (97%) maintained the frequency of the HETP
throughout their participation in the trial and across all relevant treatment cycles (as
verified by score charts). Data is missing for one family and the other discontinued the
home therapy program six weeks after receiving the second injection.
Discussion
To the best of our knowledge, this is the first standardized HETP developed for use in
a Phase-III trial of BoNT-A therapy. The anecdotal feedback from therapists has been
positive, with therapists emphasizing how the HETP helps with patient engagement and
in getting patients and families to think about how to incorporate exercises in their
daily lives. From the authors’ experience, the standard HETP format appears to be
acceptable across the diverse range of countries and cultures included in the Phase III
study. In addition, the high proportion of families reporting continued use of the HETP
throughout the trial confirms family acceptance and continued adherence to the stand-
ards of therapy outlined in the program.
The finalized HETP demonstrates that the process for developing a home therapy
program as first outlined by Novak and Cusick (2006) is useful and can be implemented
across countries and cultures. As a team of clinicians from very different countries and
cultures, we found that the development of written information sheets and commitment
forms provided a consistent way to build trust, educate, and engage with children and
their parents/caregivers. A collaborative goal setting environment was achieved through
implementation of GAS which was found to provide a structured process that all thera-
pists could readily follow. As described in several published papers, the setting and
negotiation of SMART goals is helpful in engaging and motivating the patient because
the resultant goals are worded in a way that has direct meaning to the lives of patients
and their families (Bovend’Eerdt et al., 2009; Steenbeek et al., 2007; Tilton et al., 2016;
Turner-Stokes, Fheodoroff, Jacinto, Maisonobe, & Zakine, 2013; Turner-Stokes,
Williams, & Johnson, 2009).
Our main aim was to build a comprehensive library of exercises/activities to provide
a standardized therapy program that could easily be personalized to the specific needs
of each patient, and tailored to their treatment goals. Our program was purposefully
designed to support the effectiveness of BoNT-A therapy with the idea of providing a
standardized biomechanical therapy approach for an interventional trial. It was there-
fore necessary to focus on muscle-specific exercises and activities that promote
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attainment of patient-centered goals. Exercises were chosen by the working group based
on their own clinical experience, and the manual was intended to help close a gap in
the modern literature of appropriate exercises for children following an injection of
BoNT-A into the upper limb. Function was not specifically addressed in the manual
because it is emphasized throughout the process of goal setting and goal attainment
scaling. For patients that selected active goals, therapists could embed AROM and
strengthening into activities based on the child’s interests and GAS goals. Asking the
patients and families to complete five sessions of 15minutes per week allowed for one
missed session per week, while still maintaining the frequency of practice needed for
clinically significant change (Novak et al., 2009).
Limitations of our development process include the lack of a formalized process for
cross-cultural adaptation and lack of child/family feedback on the HETP design.
Nevertheless, all active exercises were designed to be functionally useful and as fun as
possible. The working group aimed to develop exercises that could be performed at home
with readily available equipment (e.g. cups, balls, sand, and water). While the manual was
designed with a regulatory focus for use in a Phase III trial (e.g. assessing “compliance”),
it is important to note that therapists were given the flexibility to support individualized
modification of home therapy at each trial visit. In line with Step 4 of the process recom-
mended by Novak et al., parents were continually asked for feedback on the use of the
program and therapists had full capability to adapt the exercises as needed.
The high acceptance of the home therapy program (thus far) supports its feasibility
and clinical application. This trial will not provide information on the impact of the
HETP on functional attainment. It will, however, provide a standardized background of
good practice against which to test the efficacy of abobotulinumtoxinA. Recent experi-
ence in a Phase-III trial of abobotulinumtoxinA for pediatric lower limb spasticity has
shown the relevance of robust training and standardization of outcome measurement in
providing a robust dataset that can show statistically significant and clinically relevant
differences between treatment groups – both in measures of spasticity and hypertonia
and in functional measures including the GAS (Delgado et al., 2016; Tilton et al., 2016).
We also believe the HETP can be implemented to improve standards of care for chil-
dren with CP across countries and cultures, particularly where resources are limited.
Conclusions
It is widely acknowledged that children with neurologic disabilities require opportunities
for repeated practice of new tasks (Hubbard, Parsons, Neilson, & Carey, 2009), and the
home therapy approach recognizes that families are better positioned than health pro-
fessionals to perform these exercises with the frequency required for functional impact.
It should be noted that our evidence for family acceptance and continued adherence of
the program is based on interim analyses from the first 65 children who completed the
trial. The final analysis will be published separately and will provide further information
about the acceptability of the program. We hope that the full and transparent descrip-
tion of the HETP provided here will not only help with the design of future interven-
tional trials, but also provide guidance for the development of a “tried and tested”
program that has been shown to be readily accepted by patients and their families.
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